AZN Astrazeneca plc

  1. Stocks
  2. Healthcare
  3. NYSE: AZN

Price (delayed)

$184.86

Market cap

$286.72B

P/E Ratio

25.96

Dividend/share

$3.21

EPS

$7.12

Enterprise value

$312.97B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 93

AstraZeneca (LSE/STO/Nasdaq: AZN ) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal ...

Highlights
AZN's price to earnings (P/E) is 78% lower than its 5-year quarterly average of 116.5 and 3.5% lower than its last 4 quarters average of 27.0
The quick ratio rose by 20% since the previous quarter and by 11% year-on-year
AZN's debt is up by 6% since the previous quarter and by 4.8% year-on-year
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.astrazeneca.com
Peers: PFE BMY MRK JNJ

Key stats

What are the main financial stats of AZN

AZN stock price

How has the Astrazeneca stock price performed over time
Intraday
-0.33%
1 week
-1.07%
1 month
16.76%
1 year
5.42%
YTD
0.54%
QTD
14.49%

Financial performance

How have Astrazeneca's revenue and profit performed over time
Revenue
$62.38B
Gross profit
$51.12B
Operating income
$14.78B
Net income
$11.03B
Gross margin
81.9%
Net margin
17.7%
AZN's net income is up by 17% year-on-year and by 6% since the previous quarter
AZN's operating income is up by 15% year-on-year and by 6% since the previous quarter
AZN's net margin is up by 9% year-on-year and by 4.1% since the previous quarter
The operating margin has grown by 8% YoY and by 3.9% from the previous quarter

Price vs fundamentals

How does AZN's price correlate with its fundamentals

Growth

What is Astrazeneca's growth rate over time

Valuation

What is Astrazeneca stock price valuation
AZN P/E details
P/E
25.96
P/B
5.54
P/S
4.6
EV/EBIT
20.76
EV/EBITDA
14.57
EV/Sales
5.02
AZN's price to earnings (P/E) is 78% lower than its 5-year quarterly average of 116.5 and 3.5% lower than its last 4 quarters average of 27.0
Astrazeneca's EPS has increased by 17% YoY and by 6% QoQ
AZN's equity is up by 13% year-on-year and by 2.8% since the previous quarter
The stock's price to book (P/B) is 4.1% less than its last 4 quarters average of 5.8
Astrazeneca's revenue has increased by 7% YoY
The stock's price to sales (P/S) is 2.4% more than its 5-year quarterly average of 4.5

Efficiency

How efficient is Astrazeneca business performance
The return on assets is up by 10% year-on-year and by 4.4% since the previous quarter
Astrazeneca's return on sales has increased by 8% YoY and by 3.9% QoQ
The company's return on equity rose by 2.8% QoQ and by 2.3% YoY

Dividends

What is AZN's dividend history
Dividend details
DPS
$3.21
Dividend yield
1.74%
Payout ratio
45.1%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Astrazeneca financials performed over time
The company's total assets is 76% higher than its total liabilities
The quick ratio rose by 20% since the previous quarter and by 11% year-on-year
AZN's current ratio is up by 15% YoY and by 13% from the previous quarter
AZN's debt is 34% smaller than its equity
AZN's equity is up by 13% year-on-year and by 2.8% since the previous quarter
AZN's debt to equity is down by 7% year-on-year but it is up by 3.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.